Shares of Compass Pathways (CMPS) jumped 10.4% to $15.50 on September 9, bucking a down day for U.S. stocks, after the company reported that patients in its flagship psilocybin therapy trial sustained meaningful depression relief for a full year. The data bolster Compass's case as it races to complete an FDA application by year-end — but investors are betting heavily on a drug with no revenue and serious competitive and reimbursement hurdles ahead.
A Second Dose Kept Working for a Year — and That Matters for the FDA Filing. The 25 mg arm showed a mean 13-point reduction on a standard depression scale from baseline at 52 weeks.
Patients who crossed over from placebo and received their first dose also showed rapid, meaningful improvement, reinforcing the drug's single-dose potential.
No new safety signals were reported. This durability data feeds directly into the rolling drug application the company is submitting to the FDA, with the final submission expected in Q4 2026 and a potential commercial launch in the first half of 2027.
$433 Million in Cash Buys Time — but Not Forever. Compass held $433 million in cash as of June 30, 2026, enough to fund operations through launch and into 2028. That cushion matters because the company has zero revenue, spent $29.2 million on R&D in Q2 alone , and still faces DEA scheduling requirements and reimbursement challenges typical of a new launch. A delay past mid-2027 would start to erode that financial buffer significantly.
The Stock Is Still Far Below Wall Street's Targets — and Analysts Like It. According to 16 analysts, CMPS carries an average "Strong Buy" rating with a 12-month price target of $23.75 — roughly 69% above today's price.
The stock has surged 172% over the past year , yet even after today's pop it trades well below its all-time closing high of $59.20 set in December 2020.
Open-Label Design and Competition Are the Fine Print. The durability data come from an open-label extension — meaning patients knew they were getting the drug — which requires more cautious interpretation than a blinded study. Meanwhile, a rival compound from Gilgamesh Pharmaceuticals has shown promising data , and Compass competes against established treatments including J&J's esketamine nasal spray, brain stimulation devices, and standard antidepressants.
The broader treatment-resistant depression market was valued at roughly $14.5 billion in 2024 and is projected to reach $25 billion by 2035 — a large prize, but one Compass must share.
Today's rally reflects legitimate clinical progress. The open question: whether a company burning cash with no approved product can convert encouraging data into real-world sales before the window — and the balance sheet — narrows.